Daré Bioscience, Inc.
DARE
$0.72
$0.011.11%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 22.95% | -85.10% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 22.95% | -85.10% | |||
| Cost of Revenue | -37.76% | 119.60% | |||
| Gross Profit | 50.11% | -113.33% | |||
| SG&A Expenses | 15.35% | 42.58% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 0.13% | 26.31% | |||
| Operating Income | 1.03% | -103.83% | |||
| Income Before Tax | 0.57% | -108.08% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 0.57% | -108.08% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 0.57% | -108.08% | |||
| EBIT | 1.03% | -103.83% | |||
| EBITDA | 1.98% | -160.89% | |||
| EPS Basic | 3.05% | -104.76% | |||
| Normalized Basic EPS | 3.02% | -104.60% | |||
| EPS Diluted | 3.05% | -2.23% | |||
| Normalized Diluted EPS | 3.02% | -104.60% | |||
| Average Basic Shares Outstanding | 2.53% | 1.66% | |||
| Average Diluted Shares Outstanding | 2.53% | 1.66% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||